European HealthTech ecosystems: France leads funding, but capital alone does not build champions

European HealthTech funding remains concentrated in a handful of countries. Excluding the UK, the ranking is: France, Germany, Switzerland, Sweden, Spain, Netherlands, with Italy at 12th. This does not correlate with healthcare market size, where Germany leads, followed by France, Italy, and Spain.

France's dominance is driven by two outliers: Doctolib (~$870M raised, dominant in patient scheduling across France, Germany, and Italy) and Alan (~$800M raised, 700,000 members, EUR 500M+ ARR). Without these two companies, France's position looks significantly less dominant.

Spain offers an interesting counterpoint: with roughly 8x less funding than France, Spanish HealthTech companies must be dramatically more capital-efficient. Portugal's Sword Health ($3B valuation) demonstrates that Southern European companies can reach global scale with the right model.

Three factors beyond capital determine ecosystem strength.

First, networks: the density of connections between founders, clinicians, investors, and corporate buyers accelerates deal flow and knowledge transfer. France benefits from a tight Parisian HealthTech community; Germany's ecosystem is more fragmented across Berlin, Munich, and Hamburg.

Second, policies: regulatory frameworks that enable innovation (like France's early adoption of telehealth reimbursement) create market pull that capital alone cannot. Germany's complex KV system and conservative digital health adoption have slowed ecosystem development despite larger healthcare spending.

Third, industry trust: healthcare is a relationship business. Ecosystems where founders have credibility with hospital administrators, payers, and regulators move faster than those where HealthTech is still viewed with skepticism.

The European Health Data Space regulation will be the most significant catalyst for European HealthTech ecosystem development. By standardizing health data exchange across EU member states, EHDS removes one of the biggest barriers to cross-border scaling: data fragmentation.

For HealthTech companies, EHDS means a product validated in France can be deployed in Germany without rebuilding the data integration layer from scratch. For investors, it means the addressable market for any European HealthTech company effectively becomes the entire EU rather than a single country.

We expect accelerated M&A activity as companies seek to build pan-European positions before EHDS implementation deadlines. The companies that establish cross-border footprints now will have a decisive advantage.